BrainsWay Ltd. (TLV:BWAY)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 960.21M |
| Revenue (ttm) | 155.27M |
| Net Income (ttm) | 18.01M |
| Shares Out | 37.80M |
| EPS (ttm) | 0.37 |
| PE Ratio | 68.28 |
| Forward PE | 44.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 283,588 |
| Average Volume | 70,360 |
| Open | 2,480.00 |
| Previous Close | 2,480.00 |
| Day's Range | 2,480.00 - 2,644.00 |
| 52-Week Range | 1,290.00 - 2,644.00 |
| Beta | 0.33 |
| RSI | 77.71 |
| Earnings Date | Aug 13, 2025 |
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do... [Read more]
News
BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call ...
BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights
Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2...
BrainsWay Q2 2025 Earnings Preview
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial Improvement in depression scores, response and remission were a...
BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego
BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd.
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care BrainsWay is actively evaluating similar ...
BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Brian Ritchie – LifeSci Advisors LLC Hadar Levy – Chief Executive Officer Ido Marom – Chief ...
BrainsWay GAAP EPS of $0.02 in-line, revenue of $11.54M beats by $0.09M
BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights
Achieved r ecord quarterly s ales of $11. 5 million in Q 1 202 5 , an increase of 27% compared to Q 1 202 4
BrainsWay Q1 2025 Earnings Preview
BrainsWay: Strong Growth Prospects Matter Little To The Market
BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer ...
BrainsWay GAAP EPS of $0.04 beats by $0.02, revenue of $11.41M beats by $0.52M
BrainsWay reports Q4 GAAP EPS of $0.04, revenue up 26.4% Y/Y, and strong 2025 guidance. Growth in Deep TMS™ adoption driving profitability.
BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Achieved r ecord quarterly s ales of $11.4 million in Q4 2024 , an increase of 27% compared with Q4 2023
Earnings Scheduled For March 11, 2025
Companies Reporting Before The Bell • Exagen (NASDAQ: XGN) is projected to report quarterly loss at $0.24 per share on revenue of $13.85 million. • Core Molding Technologies (AMEX: CMT) is expected ...
BrainsWay Q4 2024 Earnings Preview
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain ...
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd.
BrainsWay: Cash Flow Doubts Weigh On The Stock
BrainsWay reported strong growth in the third quarter and gave solid guidance. Click here to read my analysis of BWAY stock.
BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call P...
BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights
Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLI...
Earnings Scheduled For November 12, 2024
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ: TIGR) is likely to report quarterly earnings at $0.13 per share on revenue of $98.00 million. • PLDT (NYSE: PHI) is likely to report...
BrainsWay Q3 Earnings Preview
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
Are Medical Stocks Lagging Brainsway This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY) been one of thos...